These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1347520)

  • 1. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The androgenicity of oral contraceptives: the young patient's concerns.
    Runnebaum B
    Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
    Rubio-Lotvin B; Gonzales-Ansorena R
    Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norgestimate: overview of a monophasic formulation.
    Anderson FD; Gillmer MD
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A; Desmarais JL; Derman RJ
    Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
    Corson SL
    Acta Obstet Gynecol Scand Suppl; 1990; 152():25-31. PubMed ID: 2189282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
    Andolsek KM
    Acta Obstet Gynecol Scand Suppl; 1992; 156():22-6. PubMed ID: 1324553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
    Andolsek KM; Burkman RT; Kafrissen ME; Olson W; Osterman J
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():122-5. PubMed ID: 8260970
    [No Abstract]   [Full Text] [Related]  

  • 17. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
    Gauthier A; Upmalis D; Dain MP
    Acta Obstet Gynecol Scand Suppl; 1992; 156():27-32. PubMed ID: 1324554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.